Enzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system. Enzolytics, Inc. has provided an update regarding Virogentics, Inc.'s ITV-1 African Project. The final protocol for the administration of the ITV-1 immunotherapy treatment under the supervision of Neuro Pharma Ltd - Rwanda, to be dispensed to volunteers under a fast-track protocol at HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC, has been completed and delivered to the DRC Ministry of Health Department of HIV and Aids for final approval. The vials with the necessary informational inserts are awaiting the approval of the final protocol report for distribution. The impact of the treatment on the HIV/AIDS virus present in the volunteers will be reported after the 17-week cycle is complete. The African clinical trial is expected to conclude with a final report by the end of 202412.
Learn more:
1. finance.yahoo.com
2. biospace.com
3. enzolytics.com
4. bignewsnetwork.com
5. accesswire.com
6. enzolytics.com
7. enzolytics.com
+5 more
